UTX is an important epigenetic regulator, and many human cancers harbor mutations or deletions in this gene.2 A series of recent studies have established the role of UTX as a tumor suppressor in leukemia, lymphoma, pancreatic, and lung cancers.3–7 In particular, it was also demonstrated that UTX escapes from X chromosome inactivation, therefore females have more functional copies of this tumor suppressor than do males, and different dosages of UTX in male and females contribute to cancer sex bias.5,8. This evidence concerns the gene KDM6A and lung cancer.